ReviewPituitary2017
Cabergoline in acromegaly.
Review in Pituitary, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 67 citations in OpenAlex.
- To test or not to test: what we have learnt from 50 years of dynamic testing in acromegaly.Pituitary · 2026Review
- Article
- Cabergoline-Induced Gambling Causing Increased Adrenal Crisis Episodes.JCEM case reports · 2025Article
- Central and peripheral regulation of the GH/IGF-1 axis: GHRH and beyond.Reviews in endocrine & metabolic disorders · 2025Review
- The role of dopamine release and D2 dopamine receptor in GHRH and somatostatin cells in controlling growth hormone secretion.Frontiers in endocrinology · 2025Article
- Effect of Cabergoline on weight and glucose metabolism in patients with acromegaly.Journal of endocrinological investigation · 2024Article
- Feline Comorbidities: Hypersomatotropism-induced diabetes in cats.Journal of feline medicine and surgery · 2024Review
- Validation of Myc-Associated Protein X (MAX) regulation in growth hormone secreting and nonfunctional pituitary adenoma.PloS one · 2023Article
- Hormone supply to the pituitary gland: A comprehensive investigation of female‑related tumors (Review).International journal of molecular medicine · 2022Review
- Growth hormone secreting pituitary adenomas show distinct extrasellar extension patterns compared to nonfunctional pituitary adenomas.Pituitary · 2022Article
- Efficacy of cabergoline add-on therapy in patients with acromegaly resistance to somatostatin analogs treatment and the review of literature.Archives of endocrinology and metabolism · 2022Review
- Approach to the Patient With Treatment-resistant Acromegaly.The Journal of clinical endocrinology and metabolism · 2022Article
- Somatostatin-Dopamine Chimeric Molecules in Neuroendocrine Neoplasms.Journal of clinical medicine · 2021Review
- Pasireotide in the Personalized Treatment of Acromegaly.Frontiers in endocrinology · 2021Review
- Acromegaly in the elderly patients.Endocrine · 2020Review
- Biochemical Control in Acromegaly With Multimodality Therapies: Outcomes From a Pituitary Center and Changes Over Time.The Journal of clinical endocrinology and metabolism · 2020Article
- Octreotide-Resistant Acromegaly: Challenges and Solutions.Therapeutics and clinical risk management · 2020Review
- Pasireotide-LAR in acromegaly patients treated with a combination therapy: a real-life study.Endocrine connections · 2019Article
- A Consensus Statement on acromegaly therapeutic outcomes.Nature reviews. Endocrinology · 2018Review
- Increasing frequency of combination medical therapy in the treatment of acromegaly with the GH receptor antagonist pegvisomant.European journal of endocrinology · 2018Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acromegaly, a rare disease due to growth hormone (GH) hypersecretion by a pituitary adenoma, is associated with severe comorbidity and premature death if not adequately treated. The usual first-line treatment is surgery. Various drugs, including somatostatin receptor ligands, dopamine agonists and GH receptor antagonists, are now available for use if surgery fails to suppress GH/IGF-I hypersecretion. Cabergoline, now the preferred dopamine agonist for treating hyperprolactinemia, is also used off-label for treating acromegaly. Cabergoline monotherapy is reported to normalize IGF-I levels in more than one-third of patients with acromegaly. When a somatostatin receptor ligand proves ineffective, cabergoline add-on therapy normalizes the IGF-I level in 40-50% of patients. Finally, when combined with the GH receptor antagonist pegvisomant in patients with mild uncontrolled disease, cabergoline helps to achieve normal IGF-I levels while avoiding the need for high-dose pegvisomant. Cabergoline is also inexpensive and well tolerated; in particular, it does not appear to promote heart valve disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.